STRENGTHENING EVIDENCE THROUGH HEALTH RESEARCH WHERE MOST PEOPLE ACCESS HEALTHCARE, RACGP joins consortium and calls for practice-based research network in primary health
With
Dr Michael Wright GP, President
The Royal Australian College of General Practitioners (RACGP) &
Associate Professor,
International Centre for Future Health Systems (ICFHS)
Australian Health Journal segment
Filmed in Sydney | March 2025
In February 2025, the Australian Government committed over $22 million for primary care research, including $5.2m awarded to Professor Michael Kidd, Director of the International Centre for Future Health Systems at UNSW and recently appointed Australia’s Chief Medical Officer, to lead the establishment of one of the largest research collaborations in Australia focused on improving primary care.
The Royal Australian College of GPs says a new national multidisciplinary consortium for primary care research is a positive step forward to improve patient care.
The RACGP is a member of the National Multidisciplinary Primary Care Research, Policy and Advocacy Consortium, which involves 100 primary care researchers from 20 universities from across the country.
RACGP President Dr Michael Wright said: “Every year more than 22 million Australians see a specialist GP for their essential health care, making general practice is the most accessed part of our health system.
“Yet research in general practice is vastly underrepresented and underfunded. General practice receives less than 2% of our national medical research funding.
“This new consortium is an important and exciting opportunity to design, test and innovate models of care to better meet the needs of patients across Australia, and I’m proud the RACGP is a member.
“The RACGP is calling for all political parties to commit to funding a national practice-based research network, like they have in Canada and the United Kingdom.
“These networks have proven to be immensely valuable overseas.
“We’re also calling for funding to test how multidisciplinary practice teams work at full scope in Australia, in order to improve access to care for patients.
“We know people get the best outcomes when their GP works together with their other specialists, and health professionals, and it’s especially valuable for people with chronic and complex illnesses.
Source: Highlights from RACGP media release
-
Investments to address health inequities in Prostate Cancer Care
Income, education, geographical location, and discrimination based on ethnicity, race, gender and sexual orientation, are only a fraction of factors that can negatively affect a person’s quality of cancer care. This is defined as the “equity gap” and it’s costing people their lives.
Timed to coincide with World Cancer Day 4th February 2025, Movember announced prostate cancer investment of $5.5 million. Eighteen grants (16 proposals and 2 community development grants) are slated to directly tackle inequities in prostate cancer care. The funding will be over three years with the grants spread across five countries – six in Canada, five in the United Kingdom, three in Australia, three in the United States and one in Ireland – each having a specific focus population and care area.
-
Rapid trend shift in radiology technology and accessibility
Dr Mansoor Parker obtained his medical degree from the University of Tasmania. He then completed his specialist radiology training at Nepean Hospital, Sydney with subspecialty interests in Interventional Radiology and Pain Management, Musculoskeletal, Cardiac and Abdominal Imaging. Dr Parker is a qualified specialist since 2005 and is a member of the Royal Australian and New Zealand College of Radiologists and the exclusive Australasian Musculoskeletal Imaging Group (AMSIG) as well as the Interventional Radiology Society of Australasia (IRSA).
-
New clinical research entity first to operate across both Australia and New Zealand
Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing, until now.
